{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:20:16Z","timestamp":1761060016350},"reference-count":82,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T00:00:00Z","timestamp":1379548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>T\u2010cell lymphomas make up approximately 10\u201315% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Diagnosis<\/jats:title><jats:p>The diagnosis of aggressive peripheral T\u2010cell lymphoma (PTCL) is usually made using the WHO classification. The ability of hematopathologists to reproducibly diagnosis aggressive PTCL is lower than for aggressive B\u2010cell lymphomas, with a range of 72\u201397% for the aggressive PTCLs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Risk Stratification<\/jats:title><jats:p>Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, PET scans appear to be useful as they are in aggressive B\u2010cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive PTCL is an important risk factor, with the best survival seen in anaplastic large cell lymphoma\u2014particularly young patients with the anaplastic lymphoma kinase positive subtype.<\/jats:p><\/jats:sec><jats:sec><jats:title>Risk Adapted Therapy<\/jats:title><jats:p>Anaplastic large cell lymphoma is the only subgroup to have a good response to a CHOP\u2010like regimen. Angioimmunoblastic T\u2010cell lymphoma has a prolonged disease\u2010free survival in only \u223c20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL\u2010NOS (not otherwise specified) is not one disease. Anthracycline containing regimens have disappointing results and a new approach is needed. NK\/T\u2010cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy containing regimens. Enteropathy associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy, although selected patients with enteropathy associated PTCL seem to benefit from intensive therapy. Am. J. Hematol. 88:911\u2013918, 2013. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ajh.23536","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T16:30:53Z","timestamp":1444753853000},"page":"910-918","source":"Crossref","is-referenced-by-count":19,"title":["The aggressive peripheral T\u2010cell lymphomas: 2013"],"prefix":"10.1002","volume":"88","author":[{"given":"James O.","family":"Armitage","sequence":"first","affiliation":[{"name":"Department of Medicine University of Nebraska Medical Center Omaha Nebraska"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265532487"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197410)34:8 <1488::AID-CNCR2820340822>3.0.CO;2-C"},{"issue":"2","key":"e_1_2_6_6_1","first-page":"29","article-title":"Cytological and functional criteria for the classification of malignant lymphomata","volume":"31","author":"Lennert K","year":"1975","journal-title":"Br J Cancer"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_6_8_1","volume-title":"World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe E","year":"2001"},{"key":"e_1_2_6_9_1","unstructured":"SwerdlowSH.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th ed.Lyon France:International Agency for Rsearch on Cancer;2008."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.320"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65454-5"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64441-0"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200103000-00002"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-227579"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-055145"},{"key":"e_1_2_6_17_1","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0494-8"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm265"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701344915"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08335.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq415"},{"issue":"4","key":"e_1_2_6_23_1","article-title":"FDG\u2010PET in the staging and prognosis of T\u2010cell lymphoma [Abstract]","volume":"22","author":"Casulo C","year":"2011","journal-title":"Ann Oncol"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)90553-4"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105759"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4197"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp418"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90004-1"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)91754-3"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(03)00302-4"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-335216"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65736-7"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.036"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.11.4265.bloodjournal88114265"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.021"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcpc0800380"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21062"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1764"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.5999"},{"key":"e_1_2_6_44_1","article-title":"Brentuximab Vedotin (SGN\u201035) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A phase 2 study update [Abstract]","volume":"117","author":"Advani R","year":"2011","journal-title":"Blood"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1013224"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr140"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-5-364"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08003.x"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.2686.2686"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8049"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601137658"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403936"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm579"},{"issue":"4","key":"e_1_2_6_54_1","article-title":"Response to lenalidomide in heavily pre\u2010treated angioimmunoblastic t\u2010cell\u2010lymphoma (AITL) [Abstract]","volume":"22","author":"Rentschler J","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"e_1_2_6_55_1","article-title":"Long term disease control and overall survival after early dose intensification in T\u2010NHL depend on specific entities [Abstract]","volume":"22","author":"Marks R","year":"2011","journal-title":"Ann Oncol"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.12.6219"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4628"},{"key":"e_1_2_6_58_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology for Non\u2010Hodgkins Lymphomas.(TCEL\u20101) 2011;Version 4.2011:www.NCCN.org."},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641"},{"issue":"15","key":"e_1_2_6_60_1","article-title":"Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial [Abstract]","volume":"28","author":"Foss FM","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_61_1","article-title":"The efficacy of bortezomib CHOP in patients with advanced stage T or NK\/T cell lymphomas: The results of multicenter phase II study [Abstract]","volume":"116","author":"Kim SJ","year":"2010","journal-title":"Blood"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20999"},{"key":"e_1_2_6_63_1","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht C","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.2829.2829"},{"issue":"2","key":"e_1_2_6_65_1","article-title":"Dose\u2010dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T\u2010cell lymphomas (PTCLs)\u2014Overall and subtype\u2010specific results of a phase II study from Nordic lymphoma group [Abstract]","volume":"94","author":"d'Amore F","year":"2009","journal-title":"Haematologica"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.3566.3566"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25377"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.288.288"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.95.95"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2573"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.8.2966"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053547"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982090"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.795"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231324"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1675"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn119"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109099342"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705615"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn751"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23536","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.23536","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T12:44:03Z","timestamp":1692535443000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,19]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1002\/ajh.23536"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23536","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,19]]}}}